Immutep announces Phase II study of eftilagimod alfa met primary endpoint

Immutep (IMMP) announces positive data from the EFTISARC-NEO Phase II trial were shared in a Proffered Paper oral presentation by Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland, at the 2025 European Society of Medical Oncology, ESMO, Congress in Berlin, Germany. The investigator-initiated Phase II study evaluating eftilagimod alfa with radiotherapy plus KEYTRUDA in the neoadjuvant setting for resectable soft tissue sarcoma met the primary endpoint and significantly exceeded the study’s prespecified 35% tumour hyalinization/fibrosis. In the evaluable patient population, the novel combination with efti reached a median 51.5% tumour hyalinization/fibrosis.